![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
Abstract
Introduction: MDV3100 is a rationally designed androgen receptor antagonist, which has recently been shown to improve survival in men with metastatic castration-resistant prostate cancer previously treated with docetaxel chemotherapy. Drug development for advanced prostate cancer is advancing at a rapid pace with four other novel therapies (abiraterone, cabazitaxel, alpharadin and sipuleucel-T) also shown to improve overall survival in large randomised studies.
Areas covered: This review will cover the historical background of androgen deprivation therapy, recently approved agents for advanced prostate cancer, an overview of the clinical development of MDV3100 and an analysis of how MDV3100 may fit into future treatment protocols for this disease.
Expert opinion: Full analysis of safety and efficacy data is awaited; however, MDV3100 appears to be a well-tolerated addition to the expanding portfolio of effective drugs for the treatment of advanced prostate cancer.
Declaration of interests
D Mukhenji has received consultant fees and travel support from Pfizer and Johnson&Johnson, and has also received travel support from Bayer and Sanofi Aventis. JS De Bono has received consultant fees from Ortho Biotech, Amgem, Astellas, Astra Zenica, Boehringer Induchem, Bristol-Myers Squibb, Dendreon, Exelixis, Genetech, GSK, Medivation, Merk, Novartis, Pfizer, Roche, Sanofi Aventis, SuperGen and Takeada. None of the other authors have any financial or competing interests to declare.